CureVac N.V. CVAC · Stock Open CureVac N.V. in new tab
CureVac N.V. Analysis (CVAC)
Is CureVac N.V. a good investment? CureVac N.V. (CVAC) is currently trading at 4.66 USD. Market analysts have a consensus price target of 5.40 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 6.96. This relatively low multiple may signal that CureVac N.V. is undervalued compared to historical market norms.
Earnings Schedule: CureVac N.V. is expected to release its next earnings report on April 9, 2026. The market consensus estimate for Forward EPS is -0.58.
Investor FAQ
Does CureVac N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is CureVac N.V.?
CureVac N.V. is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 9, 2026. The company currently has a trailing EPS of 0.67.
Company Profile
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was incorporated in 2000 and is headquartered in Tübingen, Germany.
Community Discussion